March 18, 2024 11:16 AM EDT
News Briefing

Blue­bird's $175M loan; Spyre re­veals sec­ond pri­vate place­ment

ENDPOINTS

Plus, news about Fen­nec, As­traZeneca, Bio­mX and Pfiz­er:

Blue­bird bio gets more mon­ey: The gene ther­a­py mak­er inked a five-year,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Chron­ic care start­up Oma­da Health files to go pub­lic

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times